# Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

> **NCT01040091** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 34 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine (FTC)
- **DRUG:** Tenofovir disoproxil fumarate (TDF)
- **DRUG:** Efavirenz (EFV)
- **DRUG:** Truvada

## Key facts

- **NCT ID:** NCT01040091
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040091, "Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01040091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*